All In Biotech

Drug Trial Radar · NCT07267026

A Study to Evaluate the Safety, Tolerability and PK of SK-09

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of SK-09 in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Dec 8, 2025

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Consun Pharmaceutical GroupIndustry
Sponsor type
Industry
First posted
Dec 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 trial consists of three parts: Part 1 is a Single Ascending Dose (SAD) study, Part 2 is a Multiple Ascending Dose (MAD) study. Both parts adopt a randomized, double-blind, placebo-controlled design. Part 3 is a randomized, open-label, single-dose, two-period crossover self-controlled design FE study.

Conditions

  • FSGS
  • MCD

Interventions

  • SK-09Drug

    SAD:Dose groups of 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, and 500 mg were given. MAD:Dose groups (low100 mg BID, 200 mg BID, and 500mg QD or 300mg BID/medium/high, based on Part 1 SAD results) will be given. FE:Dose group (150mg) was given.

  • PlaceboDrug

    SAD:Dose groups of 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, and 500 mg were given. MAD:Dose groups (low100 mg BID, 200 mg BID, and 500mg QD or 300mg BID/medium/high, based on Part 1 SAD results) were given.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety EvaluationTime frame: up to 8 days post-dosing for SAD ,up to 14 days post-dosing for MAD, up to 14 days first post-dosing for FE.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Q-Pharm Pty Ltd.

    Herston, Queensland, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.